Samsung applies for approval of Humira biosimilar
Samsung is about to secure a pipeline with biosimilars of the top 3 ‘TNF-alpha inhibitors.’
After a ‘Enbrel(etanercept)’ similar, ‘Lenflexis,’ and a ‘Remicade(infliximab)’ similar, ‘Brenzys,’ the company filed for approval of the top product ‘Humira(adalimumab)’ similar, ‘SB5.’
Samsung Bioepis...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
